CA19-9、CA125、CEA和CYFRA21-1检测对肺腺癌患者骨转移的诊断价值分析

目的 研究CA19-9、CA125、CEA和细胞角蛋白19片段(CYFRA 21-1)检测对肺腺癌患者骨转移的诊断价值,为临床诊断提供参考.方法 选取2015年1月至2015年12月在我院住院治疗的肺腺癌患者90例,对所有患者行CA19-9、CA125、CEA、CYFRA 21-1检测以及骨显像检查,对比骨转移患者与非骨转移患者四项肿瘤标志物检测情况及阳性分布.结果 骨显像阳性患者血清中CA19-9、CA125、CEA以及CYFRA 21-1四项肿瘤标志物的检测结果以及阳性率均显著高于骨显像阴性患者,且差异均具有统计学意义(P＜0.05);四项肿瘤标志物从正常浓度到1～3倍浓度再到大于3倍浓度患者的骨显像阳性率呈阶梯式上升.结论 CA19-9、CA125、CEA以及CYFRA 21-1四项肿瘤标志物在肺癌骨转移患者中的阳性率均较高,可在监测肺癌骨转移时作为参考指标.

CA19-9, CA125, CEA and CYFRA 21-1 Detection in the Diagnosis of Bone Metastasis in Patients with Lung Cancer

Objective To analyze the detection value of CA19-9,CA125,CEA and CYFRA 21-1 in the diagnosis of bone metastasis in patients with lung cancer.Methods We selected 90 cases of lung cancer,who were treated in our hospital from January 2015 to December.All subjects were tested on CA19-9,CA125,CEA,CYFRA 21-1 and bone scintigraphy.Patients with and without bone metastasis and relationship with four tumor markers were analyzed.Results Patients with positive bone imaging had significantly higher levels of CA19-9,and CA125,and CEA and CYFRA 21-1 tumor markers than those with negative bone metastasis (P ＜ 0.05).Conclusion CA19-9,CA125,CEA and CYFRA 21-1 four tumor markers are significantly higher in lung cancer patients with bone metastasis.These four tumor markers can be used as a reference index in monitoring bone metastases of lung cancer.